Susceptibility of CD24+ ovarian cancer cells to anti-cancer drugs and natural killer cells

Koh, Jai‐Kyoung; Lee, Saet byul; Park, Hyun-Ju; Lee, Hyo Jun; Cho, Nam Hoon; Kim, Jongsun

doi:10.1016/j.bbrc.2012.09.067

Cited by 29 publications

(16 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, when activating KIR, NKG2D and NCRs are ligated to their cognate ligands, the balance may be tipped towards activating signals, and this ultimately determines cytotoxic potency (19) and production of proinflammatory cytokines and chemokines. Thus, the therapeutic potential of NK cells against cancer was explored in vitro (20)(21)(22) and in vivo (23,24). Allogeneic NK cells were demonstrated to mediate the graft-versus-leukemia effect through KIR-HLA class I ligand mismatch in patients receiving hematopoietic stem cell transplantation (HSCT) (18).…”

mentioning

confidence: 99%

NK Cells with KIR2DS2 Immunogenotype Have a Functional Activation Advantage To Efficiently Kill Glioblastoma and Prolong Animal Survival

Navarro

Kmiecik

Leiss

et al. 2014

The Journal of Immunology

View full text Add to dashboard Cite

Glioblastomas (GBMs) are lethal brain cancers that are resistant to current therapies. We investigated the cytotoxicity of human allogeneic NK cells against patient-derived GBM in vitro and in vivo, as well as mechanisms mediating their efficacy. We demonstrate that KIR2DS2 immunogenotype NK cells were more potent killers, notwithstanding the absence of inhibitory killer Ig–like receptor (KIR)-HLA ligand mismatch. FACS-sorted and enriched KIR2DS2+ NK cell subpopulations retained significantly high levels of CD69 and CD16 when in contact with GBM cells at a 1:1 ratio and highly expressed CD107a and secreted more soluble CD137 and granzyme A. In contrast, KIR2DS2− immunogenotype donor NK cells were less cytotoxic against GBM and K562, and, similar to FACS-sorted or gated KIR2DS2− NK cells, significantly diminished CD16, CD107a, granzyme A, and CD69 when in contact with GBM cells. Furthermore, NK cell–mediated GBM killing in vitro depended upon the expression of ligands for the activating receptor NKG2D and was partially abrogated by Ab blockade. Treatment of GBM xenografts in NOD/SCID mice with NK cells from a KIR2DS2+ donor lacking inhibitory KIR-HLA ligand mismatch significantly prolonged the median survival to 163 d compared with vehicle controls (log-rank test, p = 0.0001), in contrast to 117.5 d (log-rank test, p = 0.0005) for NK cells with several inhibitory KIR-HLA ligand mismatches but lacking KIR2DS2 genotype. Significantly more CD56+CD16+ NK cells from a KIR2DS2+ donor survived in nontumor-bearing brains 3 wk after infusion compared with KIR2DS2− NK cells, independent of their proliferative capacity. In conclusion, KIR2DS2 identifies potent alloreactive NK cells against GBM that are mediated by commensurate, but dominant, activating signals.

show abstract

mentioning

confidence: 99%

NK Cells with KIR2DS2 Immunogenotype Have a Functional Activation Advantage To Efficiently Kill Glioblastoma and Prolong Animal Survival

Navarro

Kmiecik

Leiss

et al. 2014

The Journal of Immunology

View full text Add to dashboard Cite

show abstract

“…On the other hand, in vitro evidences from different tumour settings suggest that NK cells can selectively kill human CSCs derived from solid tumours . (Figure ) In the context of colon adenocarcinoma, CSCs have been shown to express high levels of NK activating ligands for NKp30 and NKp44 and low levels of MHC class I molecules, resulting in a robust NK cytotoxic effect both in autologous and allogenic settings .…”

Section: Natural Killer Cells and Solid Tumor Derived Cancer Stem Cellsmentioning

confidence: 99%

“…NK cell‐mediated killing of breast and osteosarcoma CSCs mainly relies on the interactions between NKG2D and its ligands expressed on CSCs, while bladder CSCs engage both NKG2D and DNAM‐1. Instead, ovarian CSCs killing depends on both NKG2D ligands upregulation and the concomitant MHC class I down‐modulation on target cells . Generally, effective killing requires NK cell activation with IL‐2 or IL‐15, highlighting the importance of a proper use of these cytokines in immunotherapy settings.…”

Section: Natural Killer Cells and Solid Tumor Derived Cancer Stem Cellsmentioning

confidence: 99%

“…110,111 On the other hand, in vitro evidences from different tumour settings suggest that NK cells can selectively kill human CSCs derived from solid tumours. [112][113][114][115][116][117][118][119][120] (Figure 2) In the context of colon adenocarcinoma, CSCs have been shown to express high levels of NK activating ligands for NKp30 and NKp44 and low levels of MHC class I molecules, resulting in a robust NK cytotoxic effect both in autologous and allogenic settings. 114 In melanoma and glioblastoma, IL-2-activated NK cells recognize and lyse CSCs through a different combination of activating signals mainly mediated by DNAM-1 and NKp46, together with the loss of classical and non-classical MHC class I molecules.…”

Section: And Solid Tumor Derived Cancer Stem Cellsmentioning

confidence: 99%

See 1 more Smart Citation

New avenues for melanoma immunotherapy: Natural Killer cells?

et al. 2020

View full text Add to dashboard Cite

Human solid malignant tumours may be particularly resistant to conventional therapies. Among solid tumours, immunological features of cutaneous melanoma have been well characterized in the past and today melanoma patients are routinely treated with the anti‐immune checkpoints immunotherapy that has completely changed metastatic melanoma treatment and prognosis. Two cytotoxic cell populations may lead to the physical elimination of tumour cell targets: cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. Tumour recognition by CTLs depends on major histocompatibility complex (MHC) class I molecules, while NK cells recognize tumours expressing low or null levels of MHC class I molecules. Despite this well‐established complementarity, NK cells are still left behind in the optimization of innovative immunotherapy approaches. NK cells are members of innate lymphoid cells (ILCs) that play a critical role in early host defence against invading pathogens and transformed cells. Recent findings suggest that NK cell frequencies directly correlate with the overall survival of ipilimumab‐treated melanoma patients. Furthermore, in vitro and in vivo evidences indicate that NK cells can selectively kill cancer stem cells, reducing tumour size and delaying metastatic progression. The aim of this review is to provide a survey of the evidences indicating NK cells as an excellent candidate to complement the newest solid tumour immunotherapy approaches.

show abstract

“…La différence de sensibilité selon CD24(-) et CD24(+) s'expliquerait par une expression différente [1] des HLA de classe I, faible sur les cellules CD24(+), importante sur les cellules CD24(-) [2] du ligand NKG2D des récepteurs des cellules NK plus importante sur les cellules CD24(+) que sur les cellules CD24(-). Les tumeurs ovariennes étant hété-rogènes avec des cellules tumorales et des cellules souches qui expriment différemment les antigènes HLA, il a été proposé de compléter une chimiothérapie, qui détruit les cellules tumorales exprimant plus ou moins HLA, par un traitement par des cellules NK activées pour éliminer les cellules souches et prévenir récidives et métastases [35].…”

Section: L'expression Des Antigènes Des Leucocytes Humains (Hla)unclassified

Aspects immunologiques du cancer de l’ovaire : perspectives thérapeutiques

Nayama¹,

Collinet

Vinatier

2016

Journal de Gynécologie Obstétrique et Biologie de la Reproducti

View full text Add to dashboard Cite

Susceptibility of CD24+ ovarian cancer cells to anti-cancer drugs and natural killer cells

Cited by 29 publications

References 24 publications

NK Cells with KIR2DS2 Immunogenotype Have a Functional Activation Advantage To Efficiently Kill Glioblastoma and Prolong Animal Survival

NK Cells with KIR2DS2 Immunogenotype Have a Functional Activation Advantage To Efficiently Kill Glioblastoma and Prolong Animal Survival

New avenues for melanoma immunotherapy: Natural Killer cells?

Aspects immunologiques du cancer de l’ovaire : perspectives thérapeutiques

Contact Info

Product

Resources

About